The phase III pacific trial is a randomized, double-blinded, placebo-controlled, multi-center trial of Imfinzi in patients with unresectable Stage III NSCLC whose disease has not progressed following platinum-based chemotherapy concurrent with
According to the drug regulator, patients with PKU suffer from an inability to break down phenylalanine (Phe) since their birth. Palynziq has been developed to reduce blood phenylalanine
The deal is expected to fetch about $520m to the US-based Cara Therapeutics. The licensing of Korsuva, an anti-itching and anti-pain injection, with VFMCRP will be only for
The Singapore Economic Development Board is supporting the development of new facility, which is the firm’s first abroad site in Asia and second site outside of China. The
The partnership uses Evotec's phenotypic screening capabilities and compound libraries. According to the terms of the long-term drug discovery and development partnership, Celgene will pay an upfront payment of
Juluca is a two-drug regimen of ViiV Healthcare’s dolutegravir and Janssen Sciences Ireland’s rilpivirine. The drug received approval to treat HIV-1 infection in adults, who are virologically suppressed (HIV-1
The approval for the thrombopoietin (TPO) receptor agonist is for adult patients who are scheduled to go through a medical or dental procedure. The regulator said Doptelet is the
The company reported positive results from phase III Haven 3 study assessing Hemlibra prophylaxis administered every week or every two weeks in people with haemophilia A without factor
The late-stage trial named SPARTAN was held by the Johnson & Johnson (J&J) subsidiary in nmCRPC patients who had a rapidly increasing PSA while receiving continuous androgen deprivation
The investment has been provided by venture capital firm The Column Group, biotech venture capital company Atlas Venture and EcoR1 Capital, a fundamental biotechnology-focused investment advisory firm. Accent
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.